Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives.
Carlo LavalleSara TrivignoGiampaolo VettaMichele MagnocavalloMarco Valerio MarianiLuca SantiniGiovanni Battista ForleoMassimo GrimaldiRoberto BadagliaccaLuigi LanataRenato Pietro RicciPublished in: Journal of clinical medicine (2021)
Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease.
Keyphrases
- atrial fibrillation
- catheter ablation
- heart failure
- left atrial
- drug administration
- oral anticoagulants
- left atrial appendage
- pulmonary hypertension
- direct oral anticoagulants
- left ventricular
- electronic health record
- congenital heart disease
- percutaneous coronary intervention
- blood pressure
- heart rate
- venous thromboembolism
- acute coronary syndrome
- combination therapy
- mitral valve
- smoking cessation
- adverse drug
- deep learning
- case control